Rock Springs Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Rock Springs Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-68,600	Closed	-$1.17M	–	101
2025 Q2	$1.17M	Sell	68,600 -90,700	-57%	-$3.87M	0.07%	83
2025 Q1	$10.2M	Sell	159,300 -148,200	-48%	-$15.6M	0.58%	50
2024 Q4	$37.4M	Hold	307,500	–	–	1.42%	25
2024 Q3	$38.4M	Buy	307,500 +23,500	+8%	+$3.25M	1.25%	31
2024 Q2	$44.9M	Sell	284,000 -43,600	-13%	-$5.6M	1.35%	30
2024 Q1	$42.4M	Hold	327,600	–	–	1.08%	35
2023 Q4	$31.6M	Sell	327,600 -64,400	-16%	-$6.18M	0.78%	43
2023 Q3	$47.5M	Sell	392,000 -33,000	-8%	-$3.73M	1.27%	28
2023 Q2	$48.7M	Sell	425,000 -17,500	-4%	-$2.26M	1.16%	29
2023 Q1	$61M	Buy	442,500 +6,500	+1%	+$843K	1.46%	25
2022 Q4	$56.5M	Buy	436,000 +6,000	+1%	+$695K	1.36%	26
2022 Q3	$47.5M	Buy	430,000 +2,000	+0.5%	+$202K	1.23%	25
2022 Q2	$32.1M	Hold	428,000	–	–	0.93%	39
2022 Q1	$33.4M	Buy	428,000 +4,000	+0.9%	+$306K	0.84%	40
2021 Q4	$38.2M	Buy	424,000 +74,000	+21%	+$6.33M	0.88%	38
2021 Q3	$32.4M	Buy	350,000 +21,250	+6%	+$1.64M	0.68%	49
2021 Q2	$25.6M	Hold	328,750	–	–	0.51%	63
2021 Q1	$24.5M	Hold	328,750	–	–	0.53%	64
2020 Q4	$56M	Sell	328,750 -16,750	-5%	-$2.48M	1.19%	26
2020 Q3	$48.5M	Hold	345,500	–	–	1.23%	28
2020 Q2	$55.4M	Hold	345,500	–	–	1.52%	14
2020 Q1	$33.8M	Hold	345,500	–	–	1.4%	24
2019 Q4	$44.6M	Buy	345,500 +8,000	+2%	+$807K	1.41%	15
2019 Q3	$25.4M	Buy	337,500 +12,500	+4%	+$1.48M	1.01%	32
2019 Q2	$49.4M	Sell	325,000 -9,500	-3%	-$1.15M	1.79%	11
2019 Q1	$39.9M	Buy	334,500 +7,500	+2%	+$964K	1.54%	12
2018 Q4	$35.7M	Buy	327,000 +16,500	+5%	+$2.06M	1.68%	12
2018 Q3	$50.1M	Buy	310,500 +13,000	+4%	+$1.78M	1.82%	12
2018 Q2	$39.3M	Buy	297,500 +39,500	+15%	+$3.73M	1.51%	15
2018 Q1	$19.1M	Hold	258,000	–	–	0.82%	42
2017 Q4	$14.4M	Sell	258,000 -1,200	-0.5%	-$63.6K	0.65%	57
2017 Q3	$11.8M	Buy	259,200 +54,200	+26%	+$2.17M	0.54%	61
2017 Q2	$6.91M	Buy	205,000 +11,000	+6%	+$358K	0.35%	84
2017 Q1	$5.74M	Buy	194,000 +2,100	+1%	+$65K	0.33%	85
2016 Q4	$5.26M	Buy	191,900 +18,900	+11%	+$759K	0.35%	76
2016 Q3	$10.6M	Buy	173,000 +42,000	+32%	+$1.27M	0.67%	51
2016 Q2	$2.5M	Hold	131,000	–	–	0.18%	110
2016 Q1	$2.56M	Buy	131,000 +23,500	+22%	+$411K	0.21%	105
2015 Q4	$4.15M	Buy	+107,500	New	+$3.49M	0.31%	95

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Rock Springs Capital Management's SRPT Position: Q3 2025 in Review

Rock Springs Capital Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 68,600 shares — an estimated $1.17M sold.

Rock Springs Capital Management first reported a position in SRPT in Q4 2015 and held it in 39 quarters. The position peaked at $61M in Q1 2023. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

Rock Springs Capital Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
Rock Springs Capital Management sold 68,600 Sarepta Therapeutics shares in Q3 2025, an estimated $1.17M.
Rock Springs Capital Management first reported a position in Sarepta Therapeutics in Q4 2015 and held it in 39 quarters.
Rock Springs Capital Management's Sarepta Therapeutics position peaked at $61M in Q1 2023.
319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Rock Springs Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.